Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

AXL inhibitor NTQ2494

An orally bioavailable and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon oral administration, AXL inhibitor NTQ2494 targets, binds to and prevents the activation of AXL. This blocks AXL-mediated signal transduction pathways, and inhibits AXL-mediated tumor cell growth, proliferation and migration, and AXL-mediated immunosuppression and immune evasion. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types and a variety of immune cells. It plays a key role in tumor cell proliferation, survival, invasion and metastasis, and its expression is associated with drug resistance and poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:NTQ 2494
NTQ-2494
NTQ2494
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search